Contributions of Early Cortical Processing and Reading Ability to Functional Status in Individuals at Clinical High Risk for Psychosis Ricardo E. Carrión, Ph.D. 1,2,3 , Barbara A. Cornblatt, Ph.D., M.B.A. 1,2,3,4 , Danielle McLaughlin, M.A. 1 , Jeremy Chang, M.A. 1 , Andrea M. Auther, Ph.D. 1,3 , Ruth H. Olsen, B.S. 1 , and Daniel C. Javitt, M.D. 5,6 1 Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore – Long Island Jewish Health System (NS-LIJHS), Glen Oaks, NY, USA 2 Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, North Shore – Long Island Jewish Health System, Manhasset, New York, 11030, USA 3 Department of Psychiatry, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY 4 Department of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY 5 Division of Experimental Therapeutics, Columbia University College of Physicians and Surgeons, New York, NY 10032 6 Division of Schizophrenia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962 Abstract Background—There is a growing recognition that individuals at clinical high risk need intervention for functional impairments, along with emerging psychosis, as the majority of clinical high risk (CHR) individuals show persistent deficits in social and role functioning regardless of transition to psychosis. Recent studies have demonstrated reduced reading ability as a potential cause of functional disability in schizophrenia, related to underlying deficits in generation of mismatch negativity (MMN). The present study extends these findings to subjects at CHR. © 2015 Published by Elsevier B.V. Address for correspondence: Ricardo E. Carrión, Ph.D., Zucker Hillside Hospital, Psychiatry Research, 75-59 263rd Street, Glen Oaks, New York 11004, Tel: 718-470-8878, Fax: 718-470-8131, RCarrion@NSHS.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Author Contributions Drs. Cornblatt and Javitt designed the study and wrote the protocol. Ms. Olsen and McLaughlin, Mr. Chang, and Drs. Carrión, Auther, and Cornblatt acquired the data. Drs. Carrión, Javitt, and Cornblatt interpreted the data. Dr. Carrión wrote the first draft of the manuscript and undertook the statistical analyses. All authors contributed to and have approved the final manuscript. Financial Disclosures Drs. Carrión, Auther, Mr. Chang, and Ms. Olsen and McLaughlin report no financial relationships with commercial interests. Dr. Cornblatt was the original developer of the CPT-IP and has been an advisor for Hoffmann-La Roche. Dr. Javitt has intellectual property rights for use of glycine, D-serine and glycine transport inhibitors in schizophrenia, holds equity in Glytech, and has received honoraria from Vindico, Clearview healthcare, Envivo, Rockpointe, and Sunovion. HHS Public Access Author manuscript Schizophr Res. Author manuscript; available in PMC 2016 May 01. Published in final edited form as: Schizophr Res. 2015 May ; 164(0): 1–7. doi:10.1016/j.schres.2015.01.030. Author Manuscript Author Manuscript Author Manuscript Author Manuscript